Author of

• 10974

  +

  P1.21 - Poster Session 1 - Diagnosis and Staging (ID 169)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10976

    +

    P1.21-002 - A survey of EGFR mutation frequency and testing practices in Asia Pacific (ID 1213)

    09:30 - 09:30  |  Author(s): S. Shuangshoti
    • Abstract

    Background
    The efficacy of EGFR TKIs in EGFR mutation-positive NSCLC patients has led to a need for accurate, timely EGFR mutation testing worldwide. Although EGFR mutation testing has been adopted by many laboratories in Asia, accurate data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. The objectives are to investigate the practice of EGFR mutation analysis in Asian Pacific countries and document the prevalence of routine testing in this population.

    Methods
    This is a retrospective database survey of records from NSCLC patients tested for EGFR mutations from 1 January 2011 to 1 January 2012 at participating sites across the Asia Pacific region. The majority of eligible hospitals/laboratories that participated had performed ≥ 100 EGFR mutation tests during that period. Accessible patient records were used to complete an online questionnaire, with data being stored in a central database. Primary objectives were to determine the number of NSCLC patients tested for EGFR mutations and the rate of EGFR mutation positivity: overall, by histological subtype, and by demography. Other variables included the number of NSCLC cases diagnosed, EGFR mutation testing methods used, and tumour sample characteristics and processing. The proportion of EGFR mutation-positive patients and 95% CI were calculated; other variables will be summarized descriptively. An interim analysis has been conducted using data collected from more than 18,000 newly diagnosed NSCLC patients at 29 sites.

    Results
    The data from surveyed sites indicates that the overall proportion of NSCLC patients tested for EGFR mutations was 31.9% (95% CI 31.2-32.6%), with an EGFR mutation positivity rate of 40.2% (95% CI 39.1-41.4%) overall, ranging from 28.7% to 53.4% (Table). Additional data on demographic and histological subgroups and current testing practices (methods, sample types, sample preparation) will be presented. [*: Wilson score confidence interval. **: Note that the sites from Vietnam (one site) and Philippines (one site) did not test ≥ 100 patients. N.D.: No data.]

    Table: Proportion of Patients Tested and EGFR Mutation Rates at Participating Sites

    Country	Total number of newly diagnosed NSCLC patients	Proportion of patients tested, % (95% CI*)	EGFR mutation positivity, % (95% CI*)
    Total	18,050	31.9 (31.2-32.6)	40.2 (39.1-41.4)
    Japan	2,379	64.8 (62.9-66.7)	30.2 (28.0-32.6)
    China	12,086	18.3 (17.6-19.0)	38.1 (36.3-39.9)
    Taiwan	2,530	52.9 (50.9-54.8)	53.4 (50.7-56.0)
    Hong Kong	399	31.1 (26.7-35.8)	49.2 (40.6-57.9)
    Malaysia	357	98.6 (96.8-99.4)	45.7 (40.6-51.0)
    Thailand	249	57.8 (51.6-63.8)	45.1 (40.6-49.8)
    Vietnam**	50	100.0 (92.9-100.0)	36.0 (24.1-49.9)
    Philippines**	N.D.	Not Known	38.9 (29.5-49.2)
    Indonesia	N.D.	Not Known	28.7 (20.8-38.2)

    Conclusion
    The data collected in this survey indicate that, in 2011, testing practices varied widely across the region, despite the well-known high incidence of the mutation. The data provide an insight into these practices and provide a reference platform on which to compare and build on for the future of EGFR mutation testing and molecular diagnosis of NSCLC in Asia Pacific.